Eleven Biotherapeutics Reports Second Quarter 2015 Financial Results

Management to host conference call today at 8:30 a.m. ET

CAMBRIDGE, Mass.-- Eleven Biotherapeutics, Inc. (EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the second quarter ended June 30, 2015, and recent business highlights.

"We are continuing to focus on advancing our ocular therapeutics pipeline. We recently initiated a pivotal Phase 3 study of EBI-005 in moderate to severe allergic conjunctivitis patients suffering from the late-phase inflammatory response and are now planning to advance development of EBI-031 for the treatment of diabetic macular edema and uveitis with an IND filing expected in the first half of 2016. Our development plans are supported by data presented recently on both EBI-005 and EBI-031 at the ARVO 2015 Annual Meeting,” said Abbie Celniker, Ph.D., President and Chief Executive Officer of Eleven Biotherapeutics. “We are excited about the potential of our novel protein therapeutic drug candidates for the treatment of ocular disease and have sufficient financial resources to continue to invest in this promising pipeline.”

Federal-Mogul Reports Second Quarter 2015 Results

• Record sales of $2 billion, up 5 percent or 16 percent in constant dollars, versus Q2 2014
• Adjusted net income from continuing operations of $59 million, or $0.35 per share, compared to $57 million in Q2 2014
• Net income of $15 million from continuing operations, or $0.09 per share, compared to net loss of $5 million in Q2 2014
• Operational EBITDA of $180 million, including $28 million of negative currency impact, compared to $184 million in Q2 2014

Southfield, Michigan, July 29, 2015. Federal-Mogul Holdings Corporation (NASDAQ: FDML) today announced financial results for the second quarter ended June 30, 2015. Net sales for the second quarter were $1,962 million, an increase of 5 percent versus the second quarter of 2014. On a constant dollar basis, net sales increased by 16 percent versus Q2 2014 due to acquisitions and organic growth. The net income from continuing operations attributable to Federal-Mogul in the quarter was $15 million or $0.09 per share.

RGS Energy Completes $5 Million Public Offering of Common Stock and Warrants

LOUISVILLE, Colo., July 1, 2015 -- RGS Energy ( RGSE ), one of the nation's leading rooftop installers of solar equipment, has completed the previously announced $5 million offering of units consisting of its Class A common stock and Series F common stock warrant at a price of $3.65 per unit.

Each unit consisted of one share of Class A common stock and a warrant to purchase 0.3 share of Class A common stock, as described in the Current Report on Form 8-K filed by the company on June 26, 2015. The warrants do not contain terms that would require the company to record derivative warrant liabilities that could reduce stockholders' equity.